# **Integrated Filing (Finance) Ind AS**

# **GPT HEALTHCARE LIMITED**

### **General Information**

Scrip code*	544131	
NSE Symbol*	GPTHEALTH	
MSEI Symbol*	NOTLISTED	
ISIN*	INE486R01017	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	08-11-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	31-10-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Second quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited	
Segment Reporting	Single segment	
Description of single segment	Healthcare Service	•
Start date of board meeting	08-11-2025	
Start time of board meeting	14:30:00	
End date of board meeting	08-11-2025	
End time of board meeting	15:30:00	
Whether cash flow statement is applicable on company	true	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether the company has any related party?	true	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	true	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	false	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	true	
Latest Date on which RPT policy is updated	23-05-2025	
Indicate Company website link for updated RPT policy of the Company	https://ilshospitals.	com/investors/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	false	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	false	Textual Information(1)

# **Text Block**

Information(1)
----------------

### Financial Results - Ind-AS

			Amount in (Lakhs)
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date	of start of reporting period	01-07-2025	01-04-2025
Date	of end of reporting period	30-09-2025	30-09-2025
Whet	ther results are audited or unaudited	Unaudited	Unaudited
Natu	re of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figure case zero shall be inserted in the said column.	es for 3 months / 6 mo	nths ended, in such
1	Income		
	Revenue from operations	11,890.80	22,601.66
	Other income	133.82	290.12
	Total income	12,024.62	22,891.78
2	Expenses		
(a)	Cost of materials consumed	2,218.58	4,285.86
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00
(d)	Employee benefit expense	2,029.77	4,071.81
(e)	Finance costs	216.37	379.65
(f)	Depreciation, depletion and amortisation expense	684.77	1,302.93
(g)	Other Expenses		
1	Other Expenses	5,368.19	10,233.23
	Total other expenses	5,368.19	10,233.23
	Total expenses	10,517.68	20,273.48
3	Total profit before exceptional items and tax	1,506.94	2,618.30
4	Exceptional items	0.00	0.00
5	Total profit before tax	1,506.94	2,618.30
6	Tax expense	1,0000	_,
7	Current tax	249.00	448.00
8	Deferred tax	197.50	341.68
9	Total tax expenses	446.50	789.68
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	Net Profit Loss for the period from continuing operations	1,060.44	1,828.62
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	Net profit (loss) from discontinued operation after tax	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	1,060.44	1,828.62
17	Other comprehensive income net of taxes	(1.19)	
18	Total Comprehensive Income for the period	1,059.25	1,826.24
19	Total profit or loss, attributable to	1,000.20	1,020.21
10	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
20	Comprehensive income for the period attributable to owners of parent		
24	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital	0.005.40	0.005.40
	Paid-up equity share capital	8,205.48	8,205.48
00	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	Earnings per share		

i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	1.29	2.23
	Diluted earnings (loss) per share from continuing operations	1.29	2.23
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	1.29	2.23
	Diluted earnings (loss) per share from continuing and discontinued operations	1.29	2.23
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results		

### **Other Comprehensive Income**

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-07-2025	01-04-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]		
1 Amount of items that will not be reclassified to profit and loss		
1 Remeasurement of the net defined benefit plan	(1.68)	(3.36)
Total Amount of items that will not be reclassified to profit and loss	(1.68)	(3.36)
2 Income tax relating to items that will not be reclassified to profit or loss	(0.49)	(0.98)
3 Amount of items that will be reclassified to profit and loss		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	(1.19)	(2.38)

### **Statement of Asset and Liabilities**

	Particulars	Half Year ended (dd- mm-yyyy)
Date of st	tart of reporting period	01-04-2025
Date of er	nd of reporting period	30-09-2025
Whether r	results are audited or unaudited	Unaudited
Nature of	report standalone or consolidated	Standalone
A	ssets	
1 N	on-current assets	
P	roperty, plant and equipment	26,157.81
С	apital work-in-progress	231.23
In	nvestment property	0.00
G	Goodwill	0.00
0	Other intangible assets	75.70
In	ntangible assets under development	7,970.51
	iological assets other than bearer plants	0.00
	nvestments accounted for using equity method	0.00
	on-current financial assets	
	lon-current investments	0.00
Tr	rade receivables, non-current	0.00
	oans, non-current	16.13
0	Other non-current financial assets	1,576.26
	Total non-current financial assets	1,592.39
	eferred tax assets (net)	0.00
0	Other non-current assets	1,579.75
	Total non-current assets	37,607.39
2 <b>C</b>	current assets	
In	nventories	1,226.34
С	current financial asset	
С	Current investments	3,168.18
	rade receivables, current	3,285.84
	ash and cash equivalents	146.32
В	ank balance other than cash and cash equivalents	40.80
	oans, current	119.10
0	Other current financial assets	331.90
	Total current financial assets	7,092.14
	current tax assets (net)	0.00
0	Other current assets	421.69
	Total current assets	8,740.17
3 N	on-current assets classified as held for sale	0.00
4 R	legulatory deferral account debit balances and related deferred tax Assets	0.00
	Total assets	46,347.56
E	quity and liabilities	
1 E	quity	
	quity attributable to owners of parent	
	quity share capital	8,205.48
0	Other equity	17,174.99
	Total equity attributable to owners of parent	25,380.47
N	on controlling interest	
	Total equity	25,380.47
	iabilities	
N	on-current liabilities	

	Company results	
	Non-current financial liabilities	
	Borrowings, non-current	1,020.17
	Trade payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0.00
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.00
	Total Trade payable	0.00
	Other non-current financial liabilities	7,103.56
	Total non-current financial liabilities	8,123.7
	Provisions, non-current	1,067.60
	Deferred tax liabilities (net)	2,268.2
	Deferred government grants, Non-current	0.00
	Other non-current liabilities	1,037.50
	Total non-current liabilities	12,497.10
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	1,007.1
	Trade payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	138.48
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	4,734.4
	Total Trade payable	4,872.93
	Other current financial liabilities	2,025.48
	Total current financial liabilities	7,905.58
	Other current liabilities	505.02
	Provisions, current	59.3
	Current tax liabilities (Net)	0.0
	Deferred government grants, Current	0.00
	Total current liabilities	8,469.99
}	Liabilities directly associated with assets in disposal group classified as held for sale	0.0
ŀ	Regulatory deferral account credit balances and related deferred tax liability	0.0
	Total liabilities	20,967.09
	Total equity and liabilities	46,347.56
	Disclosure of notes on assets and liabilities	

### **Cash flow statement indirect**

	Particulars	Half Year ended (dd- mm-yyyy)
Date o	of start of reporting period	01-04-2025
Date o	of end of reporting period	30-09-2025
Wheth	ner results are audited or unaudited	Unaudited
Nature	e of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	2,618.30
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	379.65
	Adjustments for decrease (increase) in inventories	(343.84)
	Adjustments for decrease (increase) in trade receivables, current	(834.71)
	Adjustments for decrease (increase) in trade receivables, non-current	0.00
	Adjustments for decrease (increase) in other current assets	0.00
	Adjustments for decrease (increase) in other non-current assets	(192.08)
	Adjustments for other financial assets, non-current	95.03
	Adjustments for other financial assets, current	0.00
	Adjustments for other bank balances	0.00
	Adjustments for increase (decrease) in trade payables, current	1,409.72
	Adjustments for increase (decrease) in trade payables, non-current	0.00
	Adjustments for increase (decrease) in other current liabilities	0.00
	Adjustments for increase (decrease) in other non-current liabilities	(116.49)
	Adjustments for depreciation and amortisation expense	1,302.93
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0.00
	Adjustments for provisions, current	0.00
	Adjustments for provisions, non-current	118.15
	Adjustments for other financial liabilities, current	0.00
	Adjustments for other financial liabilities, non-current	(59.69)
	Adjustments for unrealised foreign exchange losses gains	0.00
	Adjustments for dividend income	0.00
	Adjustments for interest income	(221.29)
	Adjustments for share-based payments	0.00
	Adjustments for fair value losses (gains)	(7.95)
	Adjustments for undistributed profits of associates	0.00
	Other adjustments for which cash effects are investing or financing cash flow	0.00
	Other adjustments to reconcile profit (loss)	(448.75)
	Other adjustments for non-cash items	0.00
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0.00
	Total adjustments for reconcile profit (loss)	
	Net cash flows from (used in) operations	
	Dividends received	0.00
	Interest paid	0.00
	Interest received	0.00
	Income taxes paid (refund)	776.88
	Other inflows (outflows) of cash	0.00
	Net cash flows from (used in) operating activities	3,364.68
3	Cash flows from used in investing activities	3,304.00
3	Cash flows from losing control of subsidiaries or other businesses	0.00
	Cash flows used in obtaining control of subsidiaries or other businesses	0.00

	Other cash receipts from sales of equity or debt instruments of other entities	0.00
	Other cash payments to acquire equity or debt instruments of other entities	0.00
	Other cash receipts from sales of interests in joint ventures	0.00
	Other cash payments to acquire interests in joint ventures	0.00
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0.00
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0.00
	Proceeds from sales of property, plant and equipment	10.55
	Purchase of property, plant and equipment	2,616.15
	Proceeds from sales of investment property	0.00
	Purchase of investment property	0.00
	Proceeds from sales of intangible assets	0.00
	Purchase of intangible assets	0.00
	Proceeds from sales of intangible assets under development	0.00
	Purchase of intangible assets under development	0.00
	Proceeds from sales of goodwill	0.00
	Purchase of goodwill	0.00
	Proceeds from biological assets other than bearer plants	0.00
	Purchase of biological assets other than bearer plants	0.00
	Proceeds from government grants	0.00
	Proceeds from sales of other long-term assets	0.00
	Purchase of other long-term assets	0.00
	Cash advances and loans made to other parties	0.00
	·	
	Cash receipts from repayment of advances and loans made to other parties	0.00
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0.00
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0.00
	Dividends received	0.00
	Interest received	174.04
	Income taxes paid (refund)	0.00
	Other inflows (outflows) of cash	156.40
	Net cash flows from (used in) investing activities	(2,275.16)
4	Cash flows from used in financing activities	0.00
	Proceeds from changes in ownership interests in subsidiaries	0.00
	Payments from changes in ownership interests in subsidiaries	0.00
	Proceeds from issuing shares	0.00
	Proceeds from issuing other equity instruments	0.00
	Payments to acquire or redeem entity's shares	0.00
	Payments of other equity instruments	0.00
	Proceeds from exercise of stock options	0.00
	Proceeds from exercise of stock options Proceeds from issuing debentures notes bonds etc	0.00 0.00
	·	0.00
	Proceeds from issuing debentures notes bonds etc	0.00 1,195.25
	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings	
	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings	0.00 1,195.25 496.38
	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings Payments of lease liabilities	0.00 1,195.25 496.38 491.28 1,230.82
	Proceeds from issuing debentures notes bonds etc  Proceeds from borrowings  Repayments of borrowings  Payments of lease liabilities  Dividends paid	0.00 1,195.25 496.38 491.28 1,230.82 85.85
	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings Payments of lease liabilities Dividends paid Interest paid	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00
	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings Payments of lease liabilities Dividends paid Interest paid Income taxes paid (refund)	0.00 1,195.25 496.38 491.28
	Proceeds from issuing debentures notes bonds etc  Proceeds from borrowings  Repayments of borrowings  Payments of lease liabilities  Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00 0.00 (1,109.08)
5	Proceeds from issuing debentures notes bonds etc  Proceeds from borrowings  Repayments of borrowings  Payments of lease liabilities  Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00
5	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings Payments of lease liabilities Dividends paid Interest paid Income taxes paid (refund) Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes  Effect of exchange rate changes on cash and cash equivalents	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00 0.00 (1,109.08) (19.56)
5	Proceeds from issuing debentures notes bonds etc  Proceeds from borrowings  Repayments of borrowings  Payments of lease liabilities  Dividends paid  Interest paid  Income taxes paid (refund)  Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes  Effect of exchange rate changes on cash and cash equivalents  Effect of exchange rate changes on cash and cash equivalents	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00 0.00 (1,109.08) (19.56)
5	Proceeds from issuing debentures notes bonds etc Proceeds from borrowings Repayments of borrowings Payments of lease liabilities Dividends paid Interest paid Income taxes paid (refund) Other inflows (outflows) of cash  Net cash flows from (used in) financing activities  Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes  Effect of exchange rate changes on cash and cash equivalents	0.00 1,195.25 496.38 491.28 1,230.82 85.85 0.00 0.00 (1,109.08)

# Audit qualification

	Details of Audit	Type of Audit	Frequency of	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s	) where the impact is not quantified by the auditor						
Sr.	Qualification	Qualification	qualification	Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditors Comments on (i) or (ii) above					
	No records available											

# Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

													relates	to loans, inte	r-corp	orate de s need t	ransactions - a eposits, advand o be disclosed ransaction was	ces or inv	vestme ce, duri	nts made or	elated party given by the	e listed
	Details of the party (listed entity /subsidiary entering into the transaction	) count	s of the erparty		Details of	Value of the related party	Remarks	Value of the related party	Date of Audit Committee	Value of	In case are due party as of t transa	to either a result the	incurred to	financial inde make or give e deposits, ad investments	loans,	inter-	Details of	the loan		-corporate d vestments	leposits, adv	rances or
S	:		Relationship of the counterparty with the listed entity or its subsidiary		other related party transaction	transaction as approved by the audit committee	on approval by audit committee	ratified by	Meeting where the ratification was approved	reporting period	Opening	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of		Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
	GPT Healthcare Limited	Limited	Fellow Subsidiary	Any other transaction	Payment of Lease Liability	106.20	approval has been obtained			106.20	12.46	0.00										
2	GPT Healthcare Limited	GPT Estate Private Limited	Fellow Subsidiary	Any other transaction	Security Deposit Paid	0.00	approval has been obtained			0.00	970.00	970.00										
3	GPT Healthcare Limited	GPT Estate Private Limited	Fellow Subsidiary	Advance		1.84	approval has been obtained			1.84	0.00	1.84										
2	GPT Healthcare Limited	Late Shri Dwarika Prasad Tantia	Executive Chairman	Remuneration		104.45	approval has been obtained			104.45	81.97	9.03										<u>Textual</u> <u>Information(1)</u>
Ę	GPT Healthcare Limited	Dr. Om Tantia	Managing Director	Remuneration		137.67	approval has been obtained			137.67	27.11	12.46										
6	GPT Healthcare Limited	Mr. Anurag Tantia	Executive Director	Remuneration		87.69	approval has been obtained			87.69	19.16	8.80										
7	GPT Healthcare Limited	Mrs. Kriti Tantia	Chief Financial Officer	Remuneration		58.42	approval has been obtained			58.42	15.47	5.85										
8	GPT Healthcare Limited	Mr. Ankur Sharma	Company Secretary & Compliance Officer	Remuneration			approval has been obtained			6.91	1.67	0.90										
9	GPT Healthcare Limited	Dr. Aruna Tantia	Director	Any other transaction	Doctor Payout	36.68	approval has been obtained			36.68	0.90	1.80										
1	GPT Healthcare Limited	Dr. Ghanshyam Goyal	Director	Any other transaction	Doctor Payout	72.07	approval has been obtained			72.07	14.21	9.63										
1	GPT Healthcare Limited	Dr. Ankush Bansal	Relatives of Key Management Personnel (KMP)	Any other transaction	Doctor Payout	10.28	approval has been obtained			10.28	2.23	1.02										
1	GPT Healthcare Limited		Relatives of	transaction	Doctor Payout		approval has been obtained			0.15	0.00	0.01										

	1	1		1				Company	rtosuits					
			Personnel (KMP)											
13	GPT Healthcare Limited	GPT Sons Private Limited	Holding Company	Dividend paid		807.07 Not applicable	807.07	0.00	0.00					
14	GPT Healthcare Limited	Late Shri Dwarika Prasad Tantia	Executive Chairman	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					<u>Textual</u> <u>Information(2)</u>
15	GPT Healthcare Limited	Mrs. Pramila Tantia	Relatives of Key Management Personnel (KMP)	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
16	GPT Healthcare Limited	Dr. Om Tantia	Managing Director	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
17	GPT Healthcare Limited	Dr. Aruna Tantia	Director	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
18	GPT Healthcare Limited	Mr. Shree Gopal Tantia	Director	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
19	GPT Healthcare Limited	Mrs. Vinita Tantia	Relatives of Key Management Personnel (KMP)	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
20	GPT Healthcare Limited	Mr. Ankur Sharma	Company Secretary & Compliance Officer	Dividend paid		0.00 Not applicable	0.00	0.00	0.00					
21	GPT Healthcare Limited	Dr. Aruna Tantia	Director	Any other transaction	Director Sitting Fees	1.60 Not applicable	1.60	0.00	0.00					
22	GPT Healthcare Limited	Dr. Ghanshyam Goyal	Director	Any other transaction	Director Sitting Fees	1.20 Not applicable	1.20	0.00	0.00					
23	GPT Healthcare Limited	Mr. Kashi Prasad Khandelwal	Independent Director	Any other transaction	Director Sitting Fees	3.60 Not applicable	3.60	0.00	0.00					
24	GPT Healthcare Limited	Mr. Hari Modi	Independent Director	Any other transaction	Director Sitting Fees	2.40 Not applicable	2.40	0.00	0.00					
25	GPT Healthcare Limited	Dr. Tapti Sen	Independent Director	Any other transaction	Director Sitting Fees	2.80 Not applicable	2.80	0.00	0.00					
26	GPT Healthcare Limited		Independent Director	Any other transaction	Director Sitting Fees	2.40 Not applicable	2.40	0.00	0.00					
27	GPT Healthcare Limited	Mr. Amrendra Prasad Verma	Independent Director	Any other transaction	Director Sitting Fees	2.40 Not applicable	2.40	0.00	0.00					
28	GPT Healthcare Limited	Govardhan Foundation	Entities in which Holding company / KMP exercises significant influences	Any other transaction	CSR Expenses	approval 62.69 has been obtained	62.69	0.00	20.37					
29	GPT Healthcare Limited	Education	Entities in which Holding company / KMP exercises	Any other transaction	Other Income	6.00 approval has been obtained	6.00	0.98	0.98					

significant influences											
	Total va	alue of transaction duri	ing the reportin	ng period	1,514.52						

# **Text Block**

Textual Information(1)	Executive Chairman upto August 16, 2025
<u>Textual</u> <u>Information(2)</u>	Executive Chairman upto August 16, 2025

Obje	Objects for which funds have been raised and where there has been a deviation, in the following table:										
Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Filinge	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any				
	No records available										